Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
516.64
-0.82 (-0.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
Next >
The Latest Analyst Ratings for argenx
July 20, 2023
Via
Benzinga
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
July 18, 2023
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating...
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
July 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 17, 2023
Via
Benzinga
Why Argenx Stock Is on Fire Today
July 17, 2023
A major clinical win is boosting the drugmaker's shares today.
Via
The Motley Fool
Argenx Catapults 27% To Record High As It Edges Closer To A New Multibillion-Dollar Market
July 17, 2023
Vyvgart is already approved in multiple diseases. But Argenx isn't stopping there.
Via
Investor's Business Daily
Why Is Argenx (ARGX) Stock Up 27% Today?
July 17, 2023
Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo.
Via
InvestorPlace
The Latest Analyst Ratings for argenx
June 07, 2023
Via
Benzinga
Analyst Expectations for argenx's Future
June 07, 2023
Via
Benzinga
Expert Ratings for argenx
May 31, 2023
Via
Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers
July 17, 2023
Big gains are afoot even as the markets prepare for a flat open.
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Analyst Ratings for argenx
April 21, 2023
Via
Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
July 17, 2023
Gainers
Via
Benzinga
Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today?
July 17, 2023
BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering.
Via
InvestorPlace
Why Are Argenx Shares Trading Higher Today?
July 17, 2023
Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory
Via
Benzinga
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
July 17, 2023
Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 17, 2023
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
This Emerging Market Could Be the Next Big Thing in Biotech
July 14, 2023
Medicines to treat the many symptoms of long COVID are in high demand already.
Via
The Motley Fool
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
May 05, 2023
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.